Compare BXC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXC | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | 1700 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.5M | 568.6M |
| IPO Year | 2004 | 2007 |
| Metric | BXC | EVO |
|---|---|---|
| Price | $60.76 | $1.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $88.33 | $4.21 |
| AVG Volume (30 Days) | ★ 148.2K | 68.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.54 | $20.17 |
| P/E Ratio | $137.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.78 | $1.33 |
| 52 Week High | $93.80 | $3.87 |
| Indicator | BXC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 57.74 |
| Support Level | $47.84 | $1.50 |
| Resistance Level | $62.94 | $1.97 |
| Average True Range (ATR) | 5.15 | 0.06 |
| MACD | -1.24 | 0.03 |
| Stochastic Oscillator | 2.92 | 66.67 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.